Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
about
Epigenetic modulators, modifiers and mediators in cancer aetiology and progressionMutant p53 Drives Cancer by Subverting Multiple Tumor Suppression PathwaysThe Emerging Regulation of VEGFR-2 in Triple-Negative Breast CancerMutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.Cancer: Mutant p53 and chromatin regulationSurvival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experienceIdentification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.Citrullination/Methylation Crosstalk on Histone H3 Regulates ER-Target Gene Transcription.TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.Molecularly targeted therapies for p53-mutant cancers.Chromatin dysregulation by mutant p53Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.Mutant p53 partners in crime.Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.Putting p53 in Context.p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLθ pathways.A New Way Forward in Cancer Drug Discovery: Inhibiting the SWI/SNF Chromatin Remodelling Complex.Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α.Advances in studies of tyrosine kinase inhibitors and their acquired resistance.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.Complexes formed by mutant p53 and their roles in breast cancer.The p53 Pathway in Glioblastoma
P2860
Q26766149-27FF84EF-87F9-4148-8DD3-6C564D3E57CBQ26767396-2F10683A-DFDB-424B-98A3-55B00D4EB887Q26779248-CDC68BC1-4FB3-426D-9E58-5B4F40CA3A07Q27333756-555231DA-EF9B-4CFE-95BA-8AABEA485B70Q30313610-4DB6D804-69E6-421C-84D9-6A532E775557Q30354662-65177D7C-BF4A-4A51-A092-ADECC4D25D69Q36382370-FC4E3123-577F-4757-AA82-CF07C62E1691Q37577932-1EEBC667-6901-4B21-B10A-C83F4E1E5F08Q37656224-2ED3A816-F6EC-4B79-A1CF-F59448C1825FQ38653083-E2B92023-F610-4E41-A945-2D6F6314A772Q38796261-84897D30-2802-4E33-A027-6291B96A7039Q38831709-B744E917-601E-4767-9409-7910D076EDD8Q39005896-4BF64C79-042D-4850-A5BF-34F6322DAA52Q39120148-A5081FFB-477C-4363-8FE9-AC8CEC86057BQ39229004-A0C21E1E-0302-4ACD-9F5E-9599A08786A6Q39393193-E3DAAD4C-F276-4C0B-B944-B4B1C6A01AF0Q42384902-0489087B-EEE0-4000-AC28-459456B4B30DQ42619081-8D6D7F11-3655-4C27-A459-DF3F95860187Q47107350-4B8E73B1-C39F-47C0-A0CA-1DC01827C343Q47262684-EFF7121A-3F67-460E-B7C1-69A49054F037Q47665889-9C58C2D9-B985-48DA-8F94-96E61933FEB0Q47833426-0124C6AD-0817-48C9-BA16-C37C60075578Q48243360-A9A81976-3054-43B3-804B-3B5A82D004AEQ48278066-2951B3C2-A533-4335-B0F6-8A72E401AC98Q48690318-8E006C29-B2CE-4C77-B3CA-58AC24D3C89EQ49791721-ACABA332-21F9-4C4A-AAEE-2F3B0ABAF1B4Q49887903-4E87A295-6F64-47C2-B75A-482FC237174FQ49887925-A1A836DE-9116-480A-84A6-8DDC719AA889Q55333537-B472EDD4-7C70-431A-8A2E-3534AACB4D65Q57162865-097AE04C-8108-4EB2-9716-0C6D479C22FD
P2860
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@ast
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@en
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@nl
type
label
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@ast
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@en
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@nl
prefLabel
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@ast
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@en
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@nl
P2093
P2860
P50
P356
P1433
P1476
Mutant p53 cooperates with the ...... VEGFR2 in breast cancer cells
@en
P2093
Anne-Lise Børresen-Dale
Carol Prives
Jayantha Gunaratne
Jeffrey Y Zhou
Kausik Regunath
Laxmi Silwal-Pandit
Mainul Hoque
Neil T Pfister
Olav Engebraaten
P2860
P304
P356
10.1101/GAD.263202.115
P577
2015-06-16T00:00:00Z